http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shaking Table Test and Seismic Performance Evaluation of Shanghai Tower
Chunyu, Tian,Congzhen, Xiao,Hong, Zhang,Jinzhe, Cao Council on Tall Building and Urban Habitat Korea 2012 International journal of high-rise buildings Vol.1 No.3
Shanghai Tower is a super high-rise building of 632 m height with 'mega frame-core- outrigger truss' structure system. Due to the complexity and irregularity of structure, shaking table test was carried out to investigate its seismic performance. A 1/40 scaled test model was designed, built and tested on shaking table under earthquake of small, moderate and large levels. The experimental results showed that the structure can meet the requirements of Chinese codes and reach scheduled performance objectives. Elastic and plastic time-history analysis on the structure were carried out and the results were compared to experimental results. Based on the research results some suggestions were proposed to contribute favorable effect on the seismic capacity of the structure.
( Mulan Wei ),( Xujie Liu ),( Chunyu Cao ),( Jianlin Yang ),( Yafeng Lv ),( Jiaojiao Huang ),( Yanlin Wang ),( Ye Qin ) 생화학분자생물학회(구 한국생화학분자생물학회) 2018 BMB Reports Vol.51 No.11
Recent studies showed that the PD-1/PD-L1 checkpoint blockade is a dramatic therapy for melanoma by enhancing antitumor immune activity. Currently, major strategies for the PD-1/PD-L1 blockade have mainly focused on the use of antibodies and compounds. Seeking an alternative approach, others employ endogenous proteins as blocking agents. The extracellular domain of PD-1 (ePD1) includes the binding site with PD-L1. Accordingly, we constructed a PD-1-based recombinantly tailored fusion protein (dFv-ePD1) that consists of bivalent variable fragments (dFv) of an MMP-2/9-targeted antibody and ePD1. The melanoma-binding intensity and antitumor activity were also investigated. We found the intense and selective binding capability of the protein dFv-ePD1 to human melanoma specimens was confirmed by a tissue microarray. In addition, dFv-ePD1 significantly suppressed the migration and invasion of mouse melanoma B16-F1 cells, and displayed cytotoxicity to cancer cells in vitro. Notably, dFv-ePD1 significantly inhibited the growth of mouse melanoma B16-F1 tumor cells in mice and in vivo fluorescence imaging showed that dFv-ePD was gradually accumulated into the B16-F1 tumor. Also the B16-F1 tumor fluorescence intensity at the tumor site was stronger than that of dFv. This study indicates that the recombinant protein dFv-ePD1 has an intensive melanoma-binding capability and exerts potent therapeutic efficacy against melanoma. The novel format of the PD-L1-blocked agent may play an active role in antitumor immunotherapy. [BMB Reports 2018; 51(11): 572-577]